Login / Signup

Open questions on basal insulin therapy in T2D: a Delphi consensus.

null nullRaffaella BuzzettiRiccardo CandidoKatherine EspositoAndrea GiaccariEdoardo MannucciAntonio NicolucciGiuseppina T Russo
Published in: Acta diabetologica (2024)
In a continuously evolving scenario, BI therapy still represents an important option in the management of T2D patients.
Keyphrases
  • glycemic control
  • type diabetes
  • end stage renal disease
  • newly diagnosed
  • chronic kidney disease
  • ejection fraction
  • peritoneal dialysis
  • stem cells
  • metabolic syndrome
  • mesenchymal stem cells
  • cell therapy